c-FLIP/Ku70复合体;在肝细胞癌中诱导亡的潜在分子标
Yasamin Haghir-Sharif-Zamini1, Arezoo Khosravi2, Moustapha Hassan3
1Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Archives of biochemistry and biophysics
|January 16, 2025
概括
用表观遗传药物,特别是HDAC抑制剂准c-FLIP/Ku70复合体,为克服肝细胞癌 (HCC) 中的亡抵抗提供了一种新的策略. 这种方法可能会导致新的向疗法和肝癌管理的生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 肝细胞癌 (HCC) 是癌症死亡的主要原因,通常是晚期诊断的,治疗结果不佳.
- 对HCC的传统疗法面临着耐药性和高复发率的挑战.
- 新的治疗策略和生物标志物对于改善HCC管理至关重要.
研究的目的:
- 探索针对HCC. Ku70复合物的治疗潜力.
- 审查表观遗传修饰在调节这种复杂性和诱导亡耐药性的作用.
- 突出表观遗传药物,特别是HDAC抑制剂,作为HCC治疗的有希望的方法.
主要方法:
- 对HCC,表观遗传学和分子向疗法的现有文献的审查.
- 对c-FLIP/Ku70复合体形成背后的机制及其在亡抵抗中的作用的分析.
- 检查表观遗传变化和抑制剂对复杂解离和亡诱导的影响.
主要成果:
- c-FLIP/Ku70复合物通过抑制细胞亡来促进HCC细胞的存活.
- 表观遗传失调有助于这个复杂的稳定性.
- HDAC 抑制剂可以通过 Ku70 乙化解离合c-FLIP/Ku70 复合体,从而激活亡.
结论:
- 针对c-FLIP/Ku70复合体使用表观药物,特别是HDAC抑制剂,为HCC提供了一个新的治疗途径.
- HDAC 抑制剂显示出组合疗法的潜力,并作为克服 HCC.apoptosis 耐药性的药物.
- c-FLIP无化和Ku70乙化水平可以作为HCC的有价值的诊断和预后生物标志物.
相关概念视频
01:17The Extrinsic Apoptotic Pathway
6.2K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.2K
01:31The Intrinsic Apoptotic Pathway
6.3K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.3K
01:17Phagocytosis of Apoptotic Cells
3.6K
Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or immature dendritic cells. Non-professional phagocytes such as epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes.
Normal cells contain receptors that prevent them from being recognized...
Normal cells contain receptors that prevent them from being recognized...
3.6K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:24Caspases
12.2K
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside...
12.2K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K